Ability to swallow entrectinib intact
Unable or unwilling to swallow napabucasin capsules daily.
Patients must be able to swallow tablets whole
Patients must be able to swallow capsules
Patients unable to swallow capsules whole are not eligible; nasogastric or gastric (G) tube administration is not allowed
Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
Patients must be able to swallow whole capsules
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Ability to swallow abiraterone acetate tablets as a whole
Patients must be able to swallow intact capsules
Patients who are unable to swallow whole tablets are not eligible
Patients who are unable to swallow intact tablets are not eligible
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact capsules
Patients must be able to swallow intact tablets
Able to swallow capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Ability to swallow tablets
Able to swallow ribociclib capsules
Patients must be able to swallow tablets
Eligible patients have a body surface area >= 0.7 m^2 AND be able to swallow whole tablets at the time of study enrollment
Patients who are unable to swallow whole tablets are not eligible
Patient must be able to swallow capsules
Subjects who are unable to swallow pills
Ability to swallow the investigational product tablets.
Participants must be able to swallow ribociclib capsules or tablets
Inability to swallow intact tablets
Able to swallow capsules
Inability or unwillingness to swallow capsules; patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills;\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel;\r\n* Active peptic ulcer disease;\r\n* Malabsorption syndrome
Able to swallow capsules
Inability to swallow intact tablets
The subject is unable to swallow capsules.
Ability to swallow pills or capsules
Participant is unable to swallow or absorb oral tablets.
Inability to swallow capsules
Subject is unable to swallow pills
Must be able to swallow ribociclib and everolimus capsules/tablets
Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption
Must be able to swallow LEE011 and everolimus capsules/tablets
Patients must have the ability to swallow tablets
Patients who are unable to swallow tablets or liquid are not eligible.
Patients must be able to swallow capsules; nasogastric or gastrostomy feeding (G) tube administration is not allowed
The participant is unable to swallow tablets that are whole (do not crush or chew or administer via nasogastric [NG]-tube)
Gastrointestinal disorder affecting absorption or the ability to swallow tablets
Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)
Unable or unwilling to swallow napabucasin capsules daily.
Unable or unwilling to swallow tablets as per dosing schedule
Subjects that cannot swallow tablets.
Subject is unable to swallow or absorb oral tablets normally
Ability to swallow pills/capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
Unable or unwilling to swallow tablets or capsules
Patients must be able to swallow capsules
Able to swallow tablets.
Patient must be able to swallow capsules
Patients who are unable to swallow erlotinib tablets are not eligible
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Are able to swallow capsules
Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.
Patients who are unable to swallow tablets or have a gastrointestinal disease that could hinder the absorption of enzalutamide.
Ability to swallow oral tablets without difficulty
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Patients must be able to swallow intact tablets
Patients who are not able to swallow intact tablets are not eligible
Patients must be able to swallow intact capsules
Patients must be able to swallow capsules
Unable to swallow tablets.
Are able to swallow capsules.
Inability to swallow intact tablets
Unable to swallow or take anything orally
Unable or unwilling to swallow tablets or capsules
Inability to swallow intact tablets
Inability to swallow intact tablets
Men unable to swallow pills
Has an inability to swallow tablets or capsules
Patients who are unable to swallow pills
Able to swallow intact capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
The subject is unable to swallow capsules
Unable or unwilling to swallow tablets
Able to swallow bicalutamide and ribociclib capsules/tablets.
Patient must be capable of swallowing the ruxolitinib capsules (tablets)
Be able to swallow tablets.
Must be able to swallow pills or capsules
The subject is unable to swallow tablets
Ability to swallow capsules unless enrolled in Part E
Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed
Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function
Able to swallow capsules
Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function
Are able to swallow capsules and tablets.
Patients must be able to swallow AZD1775 capsules
Ability to swallow and retain capsules.
Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible
Ability to swallow capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
PART 2 GROUP 1 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART 2 GROUP 2A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART 2 GROUP 3 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
Able to swallow the study drugs whole as tablets
Patients must be able to swallow whole tablets
Unable or unwilling to swallow tablets
Patients unable to swallow pills.
CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
Patient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.
Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily; although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medication
The subject is unable to swallow tablets
Patients who are unable to swallow pills/capsules are ineligible
Patients must be able to swallow intact capsules whole
Inability to swallow tablets or capsules
Patient must be able to swallow capsules
Ability to swallow pills or capsules
Subject is unable to swallow or absorb oral tablets normally
Inability or unwillingness to swallow capsules
Unable to swallow capsules
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
Unable to swallow tablets
Patients who cannot swallow whole tablets (i.e. medication tablets)
Unwilling or unable to swallow tablets BID
The subject is unable to swallow tablets
The subject is unable to swallow tablets
COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Ability to swallow capsules or tablets
Patient must be able to swallow capsules
Capacity to swallow
Part E: Are able to swallow capsules or tablets
Patients who are unable to swallow pills
Patients who are unable to swallow oral gel capsules are not eligible
Ability to swallow medication capsules by mouth (which may include taking nilotinib mixed in apple sauce)
Participants must be able to swallow capsules
The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption
Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)
The subject is unable to swallow tablets
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules
Patient must be able to swallow capsules
TUMOR BIOPSY SEQUENCING: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn’s disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or gastrostomy tube (G-tube) administration is not allowed
TREATMENT: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn's disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or G-tube administration is not allowed
Patients who are not able to swallow capsules or tablets
The subject is unable to swallow capsules or tablets
Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be opened
Patients must be able to swallow capsules
Must be able to swallow ribociclib and tamoxifen capsules/tablets
Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
Must be able to swallow ribociclib capsules
Subject is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis
Patients must be able to swallow capsules whole
PHASE II: Patients must be able to swallow capsules whole
Known inability to swallow capsules
Patients must be able to swallow tablets whole
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules whole
Patients who are unable to swallow pills
Unable or unwilling to swallow tablets BID
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Patients must be able to swallow capsules/tablets
Patients who are unable to swallow pills are excluded
Part C: Patients must be able to swallow intact capsules
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients must be able to swallow whole capsules and tolerate oral medications
Patients unable to swallow whole capsules
Able to swallow whole capsules
Patients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS)
Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way
are able to swallow capsules
Unable to swallow pills
Patients must have the ability to swallow tablets
Unable or unwilling to swallow tablets
Unable to swallow tablets
The subject is unable to swallow tablets
Patients must be able to swallow whole capsules
Inability to swallow capsules.
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Patients must be able to swallow whole capsules
Are able to swallow capsules and tablets.
Subject is able to swallow capsules
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Unable or unwilling to swallow BBI608 and/or BBI503 capsules daily
Any condition causing an inability to swallow tablets.
Unable or unwilling to swallow BBI608 capsules daily.
Must be able to swallow lenalidomide capsules
Unable or unwilling to swallow BBI608 capsules daily
Are able to swallow capsules
The subject is unable to swallow tablets
Unable to swallow capsules
Must be able to swallow ribociclib / placebo capsules/tablets
Patients must be able to swallow capsules
Inability to swallow capsules
Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
Inability to swallow tablets
The subject is unable to swallow tablets
Unable to swallow tablets, or diagnosed malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
Patients must be able to swallow whole capsules
Inability to swallow tablets or capsules
Inability to swallow capsules.
Able to swallow tablets
Inability to swallow tablets
Patients must be willing and able to swallow oral tablets
Patients must have the ability to swallow tablets
Inability to swallow tablets or use of a feeding tube
Patients who are unable or unwilling to swallow tablets
Unable or unwilling to swallow BBI608 capsules daily.
Able to swallow capsules
Participant is unable or unwilling to swallow tablets
Willing to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken, and should be able to swallow tablets whole, without crushing/chewing tablets
Unable or unwilling to swallow BBI503 capsules daily
Unable or unwilling to swallow BBI608 capsules daily.
The subject is unable to swallow tablets
Are able to swallow tablets
Patients must be able to swallow tablets
Patients with an inability to swallow tablets or capsules
The subject is unable to swallow capsules tablets
Patients who are unable to swallow pills
The participant is unable to swallow capsules or tablets
Patients who cannot swallow capsules
Patients who are unable to swallow pills are not eligible
Patients must be able to swallow intact capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Unable to swallow pills
Ability to swallow oral capsules
Are able to swallow capsules
Are able to swallow capsules or tablets
Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules
Patients must be able to swallow the vorinostat capsules or have a feeding tube to allow for drug suspension
Patients who are unable to swallow tablets
Inability to swallow the HKI-272 capsules
Able to swallow capsules
Able to swallow capsules
Inability to swallow capsules
Ability to swallow tablets without difficulty;
Patients must be able to swallow tablets
Able to swallow tablets
The subject is unable to swallow tablets
Patients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be opened
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patient must be able to swallow capsules whole
NON-PROGRESSED DIPG (STRATUM 2): Patient must be able to swallow capsules whole
Known inability to swallow up to five ceritinib (LDK378) capsules daily
Ability to swallow intact palbociclib capsules and bicalutamide tablets
The subject is unable to swallow tablets
Inability to swallow oral capsules
Unable to swallow tablets, or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.
Subject is unable to swallow capsules or tablets
Inability or unwillingness to swallow capsules
Patients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Able to swallow capsules and maintain adequate hydration
Patients will be excluded if they are unable to swallow capsules whole.
Unable to swallow a whole tablet or capsule.
Patients who are not able to swallow capsules or tablets
Must be able to swallow whole capsules
Ability to swallow tablets.
Unable or unwilling to swallow BBI608/placebo capsules daily.
Patients must be able to swallow capsules
Inability or unwillingness to swallow capsules
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Unable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tablets
Patients must be able to swallow tablets whole, without crushing
Patients must be able to swallow whole capsules
Patients must be able to swallow whole tablets; tablets must not be crushed or chewed
The subject is unable to swallow tablets
The subject is unable to swallow tablets
Patients must be able to swallow whole tablets and capsules
PHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsules
PHASE II: >= 2 and =< 18 years; body surface area (BSA) >= 0.55 m^2, and able to swallow whole capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
Inability to swallow tablets for everolimus arm
Patient must be able to swallow whole tablets
Patients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation
Patients must be able to swallow capsules whole; nasogastric or gastrostomy (G) tube administration is not allowed
Able to swallow whole capsules
Patients must be able to swallow tablets
Patients must be able to swallow capsules
Patients must be able to swallow tablets
Subject is able to swallow enzalutamide capsules and comply with study requirements.
Patients must be able to swallow either intact capsules or mini-tabs without chewing
Must be able to swallow tablets and capsules
Patient must have the ability to swallow multiple capsules
Participants who are unable to swallow pills
Able to swallow capsules
Inability to swallow tablets
Inability to swallow tablets
Able to swallow oral capsules without difficulty.
Able to swallow capsules
Ability to swallow oral tablets
Ability to swallow and tolerate oral tablets
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
Patient must be able to swallow capsules (phase III only)
Subjects must be able to swallow capsules/tablets
Inability or unwillingness to swallow capsules
Patients must be able to swallow whole capsules
Unable or unwilling to swallow BBI608 capsules daily
Subjects that are unable to swallow a tablet/pill
Patients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Unable to swallow capsules or disease significantly affecting gastrointestinal function